Clinical Trials
3 trialsNCT02879695 2026-05-29
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03340766 2024-10-17
HARBOUR
Amgen
Phase 1 Completed
NCT00274742 2015-01-16
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
Amgen Research (Munich) GmbH
Phase 1 Completed